Print Page   |   Contact Us   |   Sign In   |   Join iBIO
Industry News


TOP industry news from Business Wire

Riassunto: Metabolon nomina Michael Rasche presidente delle Operazioni internazionaliOpen in a New Window

RALEIGH, Carolina del Nord, e POTSDAM, Germania--(BUSINESS WIRE)--Metabolon, leader mondiale del settore della metabolomica, ha annunciato oggi che Michael Rasche è entrato a far parte della società con la qualifica di presidente delle Operazioni internazionali. Michael lavorerà alle dirette dipendenze di Rohan Hastie, presidente e amministratore delegato di Metabolon, ed entrerà a far parte dei vertici esecutivi della società. Nell’ambito del suo mandato sovrintenderà a tutte le attività comme

 

Metabolon nomeia Michael Rasche como presidente de Negócios InternacionaisOpen in a New Window

RALEIGH, N.C. & POTSDAM, Alemanha--(BUSINESS WIRE)--A Metabolon, líder mundial em metabolômica, anunciou hoje que Michael Rasche ingressou na empresa como presidente de Negócios Internacionais. Michael reportará a Rohan Hastie, presidente e diretor executivo da Metabolon, e se tornará membro da equipe executiva corporativa. Ele liderará todas as atividades de negócios internacionais da Metabolon com um forte foco na expansão de clientes e equipes. “Estamos muito empolgados em ter Michael na equ

 

#ScientistsArePeopleToo Video Series Captures Unique PersonalitiesOpen in a New Window

SASKATOON, Saskatchewan--(BUSINESS WIRE)--Ag-West Bio series of short video vignettes offer a window into the labs and lives of five Saskatchewan scientists.

 

Metabolon Appoints Michael Rasche as President of International BusinessOpen in a New Window

RALEIGH, N.C. & POTSDAM, Germany--(BUSINESS WIRE)--Michael Rasche joins Metabolon as its President of International Business.

 

Samenvatting: Alnylam Pharmaceuticals en Medison Pharma werken samen om RNAi Therapeutics in Israël op markt te brengenOpen in a New Window

ZUG, Zwitserland & PETACH TIKVA, Israël--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), het toonaangevende RNAi therapeutisch bedrijf, en Medison Pharma, de belangrijkste commerciële partner van Israël voor innovatieve geneesmiddelen, kondigde vandaag een exclusieve overeenkomst aan om ONPATTRO®, de allereerste op de markt gebrachte RNAi therapeutica in ontwikkeling in de Alnylam RNAi portefeuille, op de markt te brengen. “Ons partnerschap met Medison markeert een belangrijke st

 

Resumen: Alnylam Pharmaceuticals y Medison Pharma se asocian para comercializar las terapias de ARN interferente en IsraelOpen in a New Window

ZUG, Suiza Y PETACH TIKVA, Israel--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), compañía líder en terapias de ARN interferente, y Medison Pharma, su socio israelí líder en la comercialización de productos farmacéuticos innovadores, han anunciado hoy un acuerdo exclusivo para comercializar ONPATTRO®, el primer agente terapéutico con RNA interferente del mercado, así como otras terapias de investigación en desarrollo de la cartera de RNA interferente de Alnylam. “Nuestra asociac

 

Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346Open in a New Window

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

 

Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the DiseaseOpen in a New Window

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. “Today’s approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF,” said Reshma K

 

Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in IsraelOpen in a New Window

ZUG, Switzerland & PETACH TIKVA, Israel--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an exclusive agreement to commercialize ONPATTRO®, the first-ever commercialized RNAi therapeutic, as well as other investigational therapeutics under development in the Alnylam RNAi portfolio. “Our partnership with Medison marks an important step in o

 

Riassunto: L’ente statunitense FDA approva ONTRUZANT® (trastuzumab-dttb), il primo farmaco oncologico di Samsung Bioepis negli Stati UnitiOpen in a New Window

INCHEON, Corea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. ha annunciato oggi che l’ente statunitense preposto al controllo dei farmaci e degli alimenti (Food and Drug Administration, FDA) ha approvato ONTRUZANT® (trastuzumab-dttb), un biosimilare di HERCEPTIN® (trastuzumab), per tutte le indicazioni d’uso, ossia quale terapia adiuvante per il trattamento del carcinoma mammario con iperespressione di HER2, del carcinoma mammario metastatico e del cancro gastrico metastatico o dell’adenocaricono

 

SanBio: Addition of a Cerebral Hemorrhage Program for SB623 Regenerative Cell MedicineOpen in a New Window

TOKYO--(BUSINESS WIRE)--At a meeting held today, the Board of Directors of SanBio Co., Ltd. (hereinafter, the “Company”) resolved to add a program for treatment of chronic motor deficit from cerebral hemorrhage as a new indication for SB623, a regenerative cell medicine developed by the Group. (Hereinafter, the “Group” refers to two companies, SanBio Co., Ltd., and SanBio, Inc.) 1. Details of the Decision As part of its mission to introduce new therapeutic drugs for the central nervous system,

 

US FDA Approves ONTRUZANT® (trastuzumab-dttb), Samsung Bioepis’ First Oncology Medicine in the United StatesOpen in a New Window

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved ONTRUZANT® (trastuzumab-dttb), a biosimilar referencing HERCEPTIN® 1 (trastuzumab), across all eligible indications, namely adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease. Please s

 

Association Management Software Powered by YourMembership  ::  Legal